Semaglutide
Also known as Ozempic, Wegovy, Rybelsus
A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.
Regulatory Pathway
Dosing Protocol
Typical Dose
1-2.4 mg weekly (after titration)
Frequency
Once weekly
Duration
Long-term / chronic use
Timing & Administration
Administer via Subcutaneous injection weekly, or oral (Rybelsus). Frequency: Once weekly.
Popular Uses
Mechanism of Action
Mimics the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, reducing glucagon release, and acting on brain appetite centers to reduce hunger and increase satiety.
Research Summary
Evidence level: fda approved. Clinical status: FDA Approved - T2D, weight loss, CV risk, kidney protection; Oral Wegovy approved Dec 2025.
Side Effects & Safety
Important Warnings
- BOXED WARNING: Thyroid C-cell tumors
- Contraindicated with medullary thyroid carcinoma or MEN 2.
References
No references available.
Related Peptides
Browse all →A dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.
View profileA modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.
View profileA triple agonist activating GLP-1, GIP, and glucagon receptors for enhanced weight loss outcomes.
View profile